文献速递淋巴瘤

复发/难治性滤泡性淋巴瘤无化疗方案的疗效:网络荟萃分析

Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis.
PubMed 文献 · Br J Haematol · 2026-07-01

该网络荟萃分析纳入5项III期和1项II期试验(共2500例患者),评估7种以抗CD20为基础的联合方案治疗复发/难治性滤泡性淋巴瘤(R/R FL)的疗效与安全性。主要终点为总生存期(OS)和无进展生存期(PFS)。结果显示,以免疫激活为核心的抗CD20联合方案疗效排名最高,其中epcoritamab联合利妥昔单抗(R2)在OS、PFS和客观缓解率(ORR)上均居首位,tafasitamab联合R2次之且安全性更好。

要点

  • 以免疫激活为核心的抗CD20联合方案是无化疗策略中最有效的选择
  • epcoritamab联合R2在OS、PFS和ORR上均排名第一
  • 含抗CD19或CD20/CD3双特异性抗体的方案可能带来更深度的疾病控制

核心结论

  • 以免疫为核心、以抗CD20为锚点的联合方案是R/R FL最有效的无化疗策略。
  • 含抗CD19或CD20/CD3双特异性抗体的方案可能提供更深度的疾病控制,尤其在高危和利妥昔单抗难治性疾病中。

研究设计与样本

  • 系统综述与网络荟萃分析,纳入5项III期和1项II期试验,共2500例患者。
  • 评估7种以抗CD20为基础的联合策略,采用SUCRA值对治疗排序。

主要发现

  • epcoritamab联合R2在OS、PFS和ORR上获得最高SUCRA排名。
  • tafasitamab联合R2在各疗效终点上稳定排名第二,且安全性更好。
  • R2单药疗效中等、耐受性良好;zanubrutinib联合抗CD20疗效有限但毒性较低。
  • 以硼替佐米和copanlisib为基础的联合方案疗效排名最低,含PI3K抑制剂方案的风险获益比最不利。
  • 抗CD20单药治疗最安全但疗效最低。

临床怎么用

  • 对R/R FL选择无化疗方案时,可优先考虑以免疫激活为核心的抗CD20联合策略。
  • 高危或利妥昔单抗难治患者可能从含抗CD19或CD20/CD3双特异性抗体的联合方案中获益更多。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Relapsed/refractory follicular lymphoma (R/R FL) remains a clinically challenging condition, with progressively declining benefit across consecutive lines of therapy. While anti-Cluster of Differentiation 20 (CD20) antibodies remain the therapeutic backbone, the optimal targeted or immune-based partner remains undefined. A systematic review and network meta-analysis (NMA) of 5 phase III and 1 phase II trials (2500 patients) evaluated seven anti-CD20-based combination strategies. Primary end-points were overall survival (OS) and progression-free survival (PFS); secondary end-points included objective response rate (ORR) and grade ≥3 adverse events. Treatments were ranked using surface under the cumulative ranking (SUCRA) values. Immune-activating strategies ranked highest across efficacy end-points. Epcoritamab plus rituximab (R2) achieved the top SUCRA rankings for OS, PFS and ORR, while tafasitamab plus R2 consistently ranked second, with a better safety profile. R2 alone showed intermediate efficacy and good tolerability, whereas zanubrutinib plus anti-CD20 demonstrated modest efficacy with lower toxicity. Bortezomib and copanlisib-based combinations ranked lowest for efficacy, with phosphoinositide 3-kinase (PI3K) inhibitor-based regimens showing the least favourable benefit-risk profile. Anti-CD20 monotherapy was the safest but least effective option. This NMA indicates that immune-centric, anti-CD20-anchored combinations represent the most effective chemotherapy-free strategies for R/R FL. Combinations incorporating anti-CD19 or CD20/CD3 bispecific antibodies appear to offer deeper disease control, particularly in high-risk and rituximab-refractory disease.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Caracciolo D, Lombardo MR, Reitano G, et al. Clinical outcomes of the chemo-free approach in relapsed/refractory follicular lymphoma: A network meta-analysis. Br J Haematol. 2026. PMID: 42383996. doi:10.1111/bjh.70649

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。